Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023

Rhea-AI Summary

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced it will release its first quarter 2023 financial results on May 10, 2023 at 7:00 a.m. ET. Following this, a conference call and live webcast will take place at 8:00 a.m. ET. Interested participants must register in advance for the call, accessible via Teva's website. Teva emphasizes its commitment to developing medications that enhance lives, offering a diverse portfolio of over 3,500 products. The company has a significant global presence in both generic and innovative medicines, serving approximately 200 million people daily, supported by a complex supply chain. The press release includes a cautionary note about forward-looking statements, highlighting that actual results may differ due to various risks.

Positive

• Plans to announce first quarter 2023 financial results on May 10, 2023.
• Teva has a portfolio of over 3,500 products in nearly every therapeutic area.
• Approximately 200 million people take Teva medicines daily.

Negative

• Potential risks linked to substantial indebtedness.
• Market competition could impact future performance.

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2023 financial results on Wednesday, May 10, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This document and the conference call, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our substantial indebtedness; our business and operations in general including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2022, including in the sections captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230414005024/en/

IR Contacts



Ran Meir

+1 (267) 468-4475



Yael Ashman

+972 (3) 914 8262



Sanjeev Sharma

+1 (973) 658 2700



PR Contacts



Kelley Dougherty

+1 (973) 832-2810



Eden Klein

+972 (3) 906 2645

Source: Teva Pharmaceutical Industries Limited

FAQ

When will Teva release its first quarter 2023 financial results?

Teva will release its first quarter 2023 financial results on May 10, 2023, at 7:00 a.m. ET.

What time is Teva's conference call on May 10, 2023?

Teva's conference call will take place at 8:00 a.m. ET on May 10, 2023.

How many products does Teva have in its portfolio?

Teva has a portfolio of over 3,500 products.

How many people take Teva's medicines daily?

Approximately 200 million people take Teva medicines every day.

What are the risks mentioned in Teva's press release?

The press release notes risks related to market competition and substantial indebtedness.